Pneumococcal Awareness Council of Experts

Palo Alto University Announces Opening of Mountain View Campus

Retrieved on: 
Thursday, November 10, 2022
Quality of life, Hospital, Education, Palo Alto University, Dallas College Mountain View Campus, Faculty, School, United States Public Health Service, Research, San Francisco Bay Area, National Alliance, Organization, Topical steroid withdrawal, PALO, Board, Mental health, Pneumococcal Awareness Council of Experts, Golden Joystick Awards, PAU, Mental disorder, NAMI, Psychology, Gender, Psychotherapy, University, Student, Community health, Castro Street, Medicine

PALO ALTO, Calif., Nov. 10, 2022 /PRNewswire-PRWeb/ -- A ribbon cutting ceremony on November 10th at 11:00 a.m. will mark the Grand Opening of Palo Alto University's (PAU) new Mountain View campus at 1172 Castro Street. The new campus facility will be home to PAU's teaching and training clinics, the Gronowski Center, and PAU's E-Clinic. Formerly located in Los Altos, the Gronowski Center offers sliding-scale in-person and tela-counseling psychotherapy services for adults, couples, and children. As well as two specialty clinics: La Clinica Latina and The Gender and Sexual Identities Clinic. In addition, the campus will also house classrooms, faculty, and administrative offices and be a hub for community workshops and events. The Mountain View Campus is one of two PAU campuses, with the other located on Arastradero Road in Palo Alto.

Key Points: 
  • Palo Alto University announces the grand opening of its new Mountain View Campus.
  • PALO ALTO, Calif., Nov. 10, 2022 /PRNewswire-PRWeb/ -- A ribbon cutting ceremony on November 10th at 11:00 a.m. will mark the Grand Opening of Palo Alto University's (PAU) new Mountain View campus at 1172 Castro Street.
  • The Mountain View Campus is one of two PAU campuses, with the other located on Arastradero Road in Palo Alto.
  • Palo Alto University is grateful to the sponsors who helped lay a strong foundation for the Mountain View campus and for meeting the community's mental health needs.

Flyover Capital Grows Management Team

Retrieved on: 
Tuesday, October 19, 2021
Technology, Professional Services, Small Business, Venture Capital, Other Technology, Telecommunications, Software, Other Professional Services, Mobile, Wireless, Hardware, Finance, Pneumococcal Awareness Council of Experts, Global Entrepreneurship Summit, Technology, National, Denver 2008 Convention Host Committee, Agtech, Transport, AXA, University, Council of Judges and Prosecutors, Multimedia, Silicon, Council, Property, Women in Science Hall of Fame (U.S. State Department), Science and technology in Asia, Partner (business rank), LLC, Flybridge Capital Partners, Lightspeed Venture Partners, Culture, Investment, Renewable energy, FLYOVER CAPITAL, MONTAGE

Flyover Capital Partners, LLC (Flyover Capital), the largest early-stage venture capital firm in Kansas, is proud to welcome Tristan Mace as Managing Partner.

Key Points: 
  • Flyover Capital Partners, LLC (Flyover Capital), the largest early-stage venture capital firm in Kansas, is proud to welcome Tristan Mace as Managing Partner.
  • His decade-long background in technology, venture capital, and building businesses will be of significant value to Flyover Capital and the region.
  • Founded in 2014, Flyover Capital invests in early-stage technology opportunities located in flyover country of the United States.
  • Flyover Capital collaborates with entrepreneurs, corporations, universities, and venture capital firms who are transforming the heartlands largest industries through technology.

Merck Submits Applications for Licensure of V114, the Company’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults to the U.S. FDA and European Medicines Agency

Retrieved on: 
Monday, November 23, 2020
FDA, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Vaccines, Medical specialties, Vaccination, Pneumonia, Health care, Health, Pneumococcal conjugate vaccine, Vaccine, Antiviral drug, Pneumococcal vaccine, Pneumococcal Awareness Council of Experts, V114, Merck

These submissions for V114 help bring us closer to offering more options to help protect against pneumococcal disease.

Key Points: 
  • These submissions for V114 help bring us closer to offering more options to help protect against pneumococcal disease.
  • V114 is Mercks investigational 15-valent pneumococcal conjugate vaccine candidate for the prevention of pneumococcal disease in adults and children.
  • For more than 100 years, Merck has contributed to the discovery and development of novel medicines and vaccines to combat infectious diseases.
  • In addition to a combined portfolio of vaccines and antibacterial, antiviral and antifungal medicines, Merck has multiple programs that span discovery through late-stage development.